A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
Active, not recruiting · NCT02886065 · Registry updated 2026-10-07Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Neoplasms by Histologic Type, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, neoplasm, plasma cell neoplasm, precancerous condition, smoldering plasma cell myeloma | Active, not recruiting | Phase 1 | 2026-10-07 | NCT02886065 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Celgene | 53 |
| Massachusetts General Hospital | 758 |
| OncoPep, Inc. | 2 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beth Israel Deaconess Medical Center | Boston | United States | 45 |
| Dana-Farber Cancer Institute | Boston | United States | 626 |
| Duke University Medical Center | Durham | United States | 505 |
| Massachusetts General Hospital | Boston | United States | 1015 |
| University Hospital of Cleveland- Seidman Cancer Center | Cleveland | United States | 1 |
| Weill Cornell Medical College | New York | United States | 58 |